

<b>Personal data</b>	
First name / Surname	Gustavo Baldassarre
Work address	Centro di Riferimento Oncologico, CRO-Aviano, IRCCS Istituto Nazionale Tumori, via Gallini 2, Aviano, Italy

<b>Education</b>	
Dates	1986-1991
Title of qualification awarded	Degree in Medicine and Surgery 110/110
Name and type of organisation providing qualification	University Federico II of Naples
Dates	1991
Title of qualification awarded	License to practice the profession of medical doctor
Name and type of organisation providing qualification	University Federico II of Naples
Dates	1993-1996
Title of qualification awarded	Specialization Degree in Oncology 110/110 cum Laude
Name and type of organisation providing qualification	University Federico II of Naples
Dates	2018
Title of qualification awarded	National qualification for full professor in Applied Biology (code 05/F1)
Name and type of organisation providing qualification	Italian Ministry of University and Research (MIUR)
Dates	2018
Title of qualification awarded	National qualification for full professor in General Pathology (code 06/A2)
Name and type of organisation providing qualification	Italian Ministry of University and Research (MIUR)

<b>Work experience</b>	
Date	1991-1993
Position held	Postdoctoral fellow,
Name and type of organisation	International Institute of Genetic and Biophysic, CNR, Naples, Italy
Dates	1993-1996
Position held	Resident in clinical oncology
Name and type of organisation	Division of Medical Oncology, University of Naples Federico II, Italy
Dates	1996-1999
Position held	Postdoctoral fellow
Name and type of organisation	Fondazione G. Pascale National Cancer Institute, Naples, Italy
Dates	2000-2002
Position held	Visiting scientist
Name and type of organisation	Kimmel Cancer Center Thomas Jefferson University, Philadelphia, (USA).
Dates	2002-present
Position held	Group Leader
Name and type of organisation	Centro di Riferimento Oncologico, CRO-Aviano, IRCCS Aviano, Italy
Dates	2004-2010
Position held	External Professor of Molecular Oncology
Name and type of organisation	Biotechnology School, University of Trieste, Italy
Dates	2013-Present

Position held	External Professor
Name and type of organisation	PhD in BioMolecular Medicine, University of Trieste, Italy
Dates	2014-2015
Position held	Vice Director, Experimental Oncology 2 Unit
Name and type of organisation	Centro di Riferimento Oncologico, CRO-Aviano, IRCCS Aviano, Italy
Dates	January 2015-March 2017
Position held	Ad interim Director, Experimental Oncology 2 Unit
Name and type of organisation	Centro di Riferimento Oncologico, CRO-Aviano, IRCCS Aviano, Italy
Dates	January 2015-Present
Position held	Expert member of the institutional animal care and use committee (OPBA)
Name and type of organisation	Centro di Riferimento Oncologico, CRO-Aviano, IRCCS Aviano, Italy
Dates	March 2017-Present
Position held	Director, Molecular Oncology Unit
Name and type of organisation	Centro di Riferimento Oncologico, CRO-Aviano, IRCCS Aviano, Italy

<b>Honors</b>	
Date	1998
Position held	Postdoctoral fellowship,
Name and type of organisation	FIRC (Fondazione Italiana ricerca sul cancro), Italy
Dates	2002
Position held	Scholar-in-Training Award
Name and type of organisation	AACR (American Association for Cancer Research)
Place	2002 Annual Meeting in San Francisco, CA, USA
Dates	2003
Position held	Young Investigator Award for Cancer Research
Name and type of organisation	SIC (Società Italiana di Cancerologia)
Place	2003 Annual Meeting in Bergamo, Italy
Dates	2005
Position held	"Highly Commended" award
Name and type of organisation	EACR (European Association for Cancer Research)
Place	2005 Annual Meeting in Paris, France

<b>Societies Membership</b>	
Date	2001-Present
Name and type of organisation	Active member, American Association for Cancer Research (AACR).
Date	2003-Present
Name and type of organisation	Member, Italian Society for Cancer Research (SIC).
Date	2020-Present
Name and type of organisation	Member of the Board of Directors and President Elect Italian Society for Cancer Research (SIC).
Date	2003-Present
Name and type of organisation	Member, European Association for Cancer Research (EACR).
Date	2014-2015
Name and type of organisation	Member, European Society for Translational Medicine (EUSTM).
Date	2020-Present

Name and type of organisation	Member of the Board of Directors of the MITO group.
-------------------------------	---

<b>Reviewer Activity</b>	
Date	2008-Present
Name and type of organisation	External reviewer for MIUR (Italian Minister on University and Research).
Date	2011-2018
Name and type of organisation	Member, Scientific Committee (CTS) of AIRC (Associazione Italiana Ricerca sul Cancro)
Date	2005-Present
Name and type of organisation	Ad hoc reviewer for several international journals in the fields of oncology, molecular and cellular biology.
Date	2019-Present
Name and type of organisation	Editor for Diagnostics
Date	2021- Present
Name and type of organisation	Associate Editor for Molecular Cancer

<b>Active Personal Grant Support</b>	
Title of the Project	Overcoming PARPi resistance in ovarian cancer: from biology to clinical application
Funding organization	Ministero della Salute, Italy
Date and role	20.05.2023- 19.05. 2025 PI
Title of the Project	Non-cell cycle CDKs as therapeutic targets and predictive biomarkers during ovarian cancer progression
Date and role	02.01.2022 al 01.01.2027 Role: PI
Funding organization	Associazione Italiana Ricerca sul Cancro (AIRC), Italy
Title of the Project	Sviluppo e industrializzazione farmaci innovativi per terapia molecolare personalizzata (Acronimo: PA. CRO. DE.)
Date and role	01.01.2021 al 30.06.2023 Role: Unit-PI
Funding organization	Ministero Italiano, Università e Ricerca (MIUR), Italy
Title of the Project	<i>PROOF-OF-CONCEPT IRCCS FRIULI-VENEZIA GIULIA (IRCCS-FVG-PoC) PoC n. 2 "Metodo per identificare soggetti resistenti al trattamento con farmaci a base di platino e relativo kit (Acronimo: MIRPLA-KIT)</i>
Date and role	25.01.2021 to 24.07.2022 Role: PI
Funding organization	MISE/INVITALIA
Title of the Project	Understanding Ovarian Cancer dissemination and chemoresistance: Opportunities to improve patients' survival
Date and role	02.01.2019 al 31.12.2022 Role: PI
Funding organization	Ministero degli Esteri e Cooperazione Internazionale, Italy
Title of the Project	Olaparib in wild type germinal and somatic BRCS platinum sensitive recurrence ovarian cancer: a MITO (Multicenter Italian Trials in Ovarian Cancer) study"
Date and role	30.03.2020 al 29.03.2024 Role: Collaborator
Funding organization	Ministero della Salute, Italy
Title of the Project	Studio di fattibilità per la diagnosi genomica congiunta di rischio genetico e di sensibilità ai

	nuovi farmaci nelle neoplasie del seno, ovaio e colon" - GERSOM per gli IRCCS della Rete Alleanza Contro il Cancro (ACC).
Date and role	03.12.2019 al 02.12.2022 Role: Unit PI
Funding organization	Ministero della Salute, Italy - Alleanza Contro il Cancro
Title of the Project	Identificazione e validazione di nuove strategie per aumentare attivazione, Espansione, sopravvivenza, penetrazione nei tessuti e azione citotossica delle cellule CAR-T: "Strategies to promote the penetration and persistence of CAR cells in solid tumors: Epithelial Ovarian Carcinomas"
Date and role	27.11.2019 al 26.11.2022 Role: Sub project PI
Funding organization	Ministero della Salute, Italy - Alleanza Contro il Cancro
Title of the Project	PE-2016-0236104 Understanding Ovarian Cancer dissemination and chemoresistance: Opportunities to improve patients' survival
Date and role	03.01.2018 al 31.12.2022 Role: PI
Funding organization	Ministero della Salute, Italy

<b>Authorized Animal Experimentation Projects</b>	
Title of the Project	Nuovi approcci bersaglio-specifici per superare la chemio resistenza nei tumori ovarici
Date and role	12.08.2015 al 01.02.2022 Role: PI
Name and type of organisation providing qualification	Ministero della Salute, Italy (Aut. Min. N. 1261/2015-PR)
Title of the Project	Modelli sperimentali per lo studio dei tumori al seno: la relazione tra cellule tumorali e microambiente nella comparsa e nella progressione del tumore
Date and role	03.07.2015 al 02.07.2020 Role: Collaboratore
Name and type of organisation providing qualification	Ministero della Salute, Italy (Aut. Min. N. 616/2015-PR)
Title of the Project	Caratterizzazione biologica dei tumori al seno: modelli per studiare la diversità molecolare per personalizzare la terapia
Date and role	12.08.2020 al 11.08.2023 Role: Collaboratore
Name and type of organisation providing qualification	Ministero della Salute, Italy (Aut. Min. N. 838/2020-PR)
Title of the Project	Ruolo delle alterazioni genetiche ed epigenetiche nella crescita e risposta alle terapie dei tumori ovarici
Date and role	01.10.2021 al 30.09.2024 Role: PI
Name and type of organisation providing qualification	Ministero della Salute, Italy (Aut. Min. N. 753/2021-PR)

<b>Publication</b>	
<b>General Information</b>	Author of 132 publications in peer reviewed international journal (1992-2021); H-Index = 47 (Google Scholar); or 42 (Scopus); Total Impact Factor (IF 2020) = 1190.9; Mean IF = 10.2.

**B. Last 5 years Peer-reviewed Publications.** (In reverse chronological order)

**132.** Capoluongo ED, Pellegrino B, Arenare L, Califano D, Scambia G, Beltrame L, Serra V, Scaglione GL, Spina A, Cecere SC, De Cecio R, Normanno N, Colombo N, Lorusso D, Russo D, Nardelli C, D'Incalci M, Llop-Guevara A, Pisano C, **Baldassarre G**, Mezzanzanica D, Artioli G, Setaro M, Tasca G, Roma C, Campanini N, Cinieri S, Sergi A, Musolino A, Perrone F, Chiodini P,

Marchini S, Pignata S. Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/ManGO-OV2 trial. *ESMO Open*. 2022;7(5):100585.

131. Pane K, Zanfardino M, Grimaldi AM, **Baldassarre G**, Salvatore M, Incoronato M, Franzese M. Discovering Common miRNA Signatures Underlying Female-Specific Cancers via a Machine Learning Approach Driven by the Cancer Hallmark ERBB. *Biomedicines*. 2022 Jun 2;10(6):1306. doi: 10.3390/biomedicines10061306

130. Rampioni Vinciguerra GL, Sonogo M, Segatto I, Dall'Acqua A, Vecchione A, **Baldassarre G**, Belletti B. CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review. *Front Oncol*. 2022 May 27;12:891580. doi: 10.3389/fonc.2022.891580.

129 Sgubin M, Pegoraro S, Pellarin I, Ros G, Sgarra R, Piazza S, **Baldassarre G**, Belletti B, Manfioletti G. HMGA1 positively regulates the microtubule-destabilizing protein stathmin promoting motility in TNBC cells and decreasing tumour sensitivity to paclitaxel. *Cell Death Dis*. 2022 May 3;13(5):429. doi: 10.1038/s41419-022-04843-4.

128 Schettino C, Musacchio L, Bartoletti M, Chiodini P, Arenare L, **Baldassarre G**, Califano D, Capoluongo E, Costi MP, D'Incalci M, Marchini S, Mezzanatica D, Normanno N, Scala S, Greggi S, Perrone F, Pignata S. Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups. *Int J Gynecol Cancer*. 2022 Mar 22;ijgc-2022-003435. doi: 10.1136/ijgc-2022-003435.

127 Califano D, Gallo D, Rampioni Vinciguerra GL, De Cecio R, Arenare L, Signoriello S, Russo D, Ferrandina G, Citron F, Losito NS, Gargiulo P, Simeon V, Scambia G, Cecere SC, Montella M, Colombo N, Tognon G, Bignotti E, Zannoni GF, Canzonieri V, Ciucci A, Spina A, Scognamiglio G, Del Sesto M, Schettino C, Piccirillo MC, Perrone F, Chiodini P, Pignata S, **Baldassarre G**. Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational Study. *Cancers (Basel)*. 2021 Oct 14;13(20):5152. doi: 10.3390/cancers13205152.

126 Rampioni Vinciguerra GL, Dall'Acqua A, Segatto I, Mattevi MC, Russo F, Favero A, Cirombella R, Mungo G, Viotto D, Karimbayli J, Pesce M, Vecchione A, Belletti B, **Baldassarre G**. p27kip1 expression and phosphorylation dictate Palbociclib sensitivity in KRAS-mutated colorectal cancer. *Cell Death Dis*. 2021 Oct 15;12(10):951. doi: 10.1038/s41419-021-04241-2.

125 De Carlo E, Schiappacassi M, Pelizzari G, Baresic T, Del Conte A, Stanzione B, DA Ros V, Doliana R, **Baldassarre G**, Bearz A. Acquired EGFR C797G Mutation Detected by Liquid Biopsy as Resistance Mechanism After Treatment With Osimertinib: A Case Report. *In Vivo*. 2021 Sep-Oct;35(5):2941-2945. doi: 10.21873/invivo.12586.

124 Dall'Acqua Bartoletti M, Masoudi-Khoram N, Sorio R, Puglisi F, Belletti B, **Baldassarre G**. Inhibition of CDK4/6 as Therapeutic Approach for Ovarian Cancer Patients: Current Evidences and Future Perspectives. *Cancers* 2021, 13(12), 3035

123 Citron F, Segatto I, Musco L, Pellarin I, Rampioni Vinciguerra GL, Franchin G, Fanetti G, Miccichè F, Giacomarra V, Lupato V, Favero A, Concina I, Srinivasan S, Avanzo M, Castiglioni I, Barzan L, Sulfaro S, Petrone G, Viale A, Draetta GF, Vecchione A, Belletti B, **Baldassarre G**. miR-9 modulates and predicts the response to radiotherapy and EGFR inhibition in HNSCC. *EMBO Mol Med*. 2021 Jun 1:e12872. doi: 10.15252/emmm.202012872.

122 Bianchi F, Dama E, Di Nicolantonio F, **Baldassarre G**, Guerriero I, Torchiano E, Bruno A, Blandino G, Allavena P, Chiarugi P, Sozzi G, D'Incalci M, Normanno N. COVID-19 epidemic strongly affected cancer research in Italy: a survey of the Italian Cancer Society (SIC). *ESMO Open*. 2021 Jun;6(3):100165. doi: 10.1016/j.esmoop.2021.100165.

121 Giglio S, De Nunzio C, Cirombella R, Stoppacciaro A, Faruq O, Volinia S, **Baldassarre G**, Tubaro A, Ishii H, Croce CM, Vecchione A. A preliminary study of micro-RNAs as minimally invasive biomarkers for the diagnosis of prostate cancer patients. *J Exp Clin Cancer Res*. 2021 Feb 23;40(1):79. doi: 10.1186/s13046-021-01875-0.

120 Lupato V, Polesel J, La Torre FB, Fanetti G, Fratta E, Gobitti C, Baldassarre G, Vaccher E, Franchin G, Giacomarra V. A pre-operative prognostic score for the selection of patients for salvage surgery after recurrent head and neck squamous cell carcinomas. *Sci Rep*. 2021 Jan 12;11(1):502. doi: 10.1038/s41598-020-79759-0.

119 Lombardi R, Sonogo M, Pucci B, Addi L, Iannelli F, Capone F, Alfano L, Roca MS, Milone MR, Moccia T, Costa A, Di Gennaro E, Bruzzese F, **Baldassarre G\*** and Budillon A\*. HSP90 identified by a proteomic approach as druggable target to reverse platinum-resistance in ovarian cancer. *Molecular Oncology* 2021 Apr;15(4):1005-1023. doi: 10.1002/1878-0261.12883.

118 Viotto D, Russo F, Anania I, Segatto I, Rampioni Vinciguerra GL, Dall'Acqua A, Bomben R, Perin T, Cusan M, Schiappacassi M, Gerratana L, D'Andrea S, Citron F, Vit F, Musco L, Mattevi MC, Mungo G, Nicoloso MS, Sonogo M, Massarut S, Sorio R, Barzan L, Franchin G, Giorda G, Lucia E, Sulfaro S, Giacomarra V, Polesel J, Toffolutti F, Canzonieri V, Puglisi F, Gattei V, Vecchione A, Belletti B, **Baldassarre G**. CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer. *J Pathol*. 2021 Feb;253(2):234-245. doi: 10.1002/path.5584.

117 Pellarin I, Belletti B, **Baldassarre G**. RNA splicing alteration in the response to platinum chemotherapy in ovarian cancer: A possible biomarker and therapeutic target. *Med Res Rev*. 2021 Jan;41(1):586-615. doi: 10.1002/med.21741.

116 Gerratana L, Basile D, Franzoni A, Allegri L, Viotto D, Corvaja C, Bortot L, Bertoli E, Buriolla S, Targato G, Da Ros L, Russo S, Bonotto M, Belletti B, **Baldassarre G**, Damante G, Puglisi F. Plasma-based longitudinal evaluation of ESR1 epigenetic status in hormone receptor positive HER2 negative metastatic breast cancer. *Frontiers in Oncology*. 2020 Sep 18;10:550185. doi: 10.3389/fonc.2020.550185.

115 Ranzuglia V, Lorenzon I, Pellarin I, Sonogo M, Dall'Acqua A, D'Andrea S, Lovisa S, Segatto I, Coan M, Polesel J, Serraino D, Sabatelli P, Spessotto P, Belletti B, **Baldassarre G\***, Schiappacassi M\*. Serum- and Glucocorticoid- inducible Kinase 2, SGK2, is

- a novel autophagy regulator and modulates platinum drugs response in cancer cells. *Oncogene*. 2020 39(40):6370-6386. doi: 10.1038/s41388-020-01433-6.. \* Co-Last author
- 114** Masoudi-Khoram N, Abdolmaleki P, Hosseinkhan N, Nikoofar A, Mowla SJ, Monfared H, **Baldassarre G**. Differential miRNAs expression pattern of irradiated breast cancer cell lines is correlated with radiation sensitivity. *Sci Rep*. 2020 Jun 3;10(1):9054. doi: 10.1038/s41598-020-65680-z.
- 113** Bartoletti M, Pelizzari G, Gerratana L, Bortot L, Lombardi D, Nicoloso M, Scalone S, Giorda G, **Baldassarre G**, Sorio R, Puglisi F. Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. *Int J Mol Sci*. 2020 May 27;21(11):E3805. doi: 10.3390/ijms21113805.
- 112** Pellarin I, Dall'Acqua A, Gambelli A, Pellizzari I, D'Andrea S, Sonogo M, Lorenzon I, Schiappacassi M, Belletti B, **Baldassarre G**. Splicing Factor Proline and Glutamine rich (SFPQ) protein regulates platinum response in ovarian cancer modulating SRSF2 activity. *Oncogene*. 2020 May;39(22):4390-4403.
- 111** Lorenzon I, Pellarin I, Pellizzari I, D'Andrea S, Belletti B, Sonogo M, **Baldassarre G\***, Schiappacassi M\*. Identification and Characterization of a New Platinum-Induced TP53 Mutation in MDAH Ovarian Cancer Cells. *Cells*. 2019 Dec 21;9(1). pii: E36. doi: 10.3390/cells9010036. \* Co-Last author
- 110** Citron F, Segatto I, Vinciguerra GLR, Musco L, Russo F, Mungo G, D'Andrea S, Mattevi MC, Perin T, Schiappacassi M, Massarut S, Marchini C, Amici A, Vecchione A, **Baldassarre G\***, Belletti B\*. Downregulation of miR-223 Expression Is an Early Event during Mammary Transformation and Confers Resistance to CDK4/6 Inhibitors in Luminal Breast Cancer. *Cancer Res*. 2020 Mar 1;80(5):1064-1077. \* Co-Last author
- 109** Sonogo M, Poletto E, Pivetta E, Nicoloso MS, Pellicani R, Vinciguerra GLR, Citron F, Sorio R, Mongiat M, **Baldassarre G**. TIMP-1 is Overexpressed and Secreted by Platinum Resistant Epithelial Ovarian Cancer Cells. *Cells*. 2019 Dec 18;9(1). pii: E6. doi: 10.3390/cells9010006.
- 108** Pivetta E, Capuano A, Scanziani E, Minoli L, Andreuzzi E, Mongiat M, **Baldassarre G**, Doliana R, Spessotto P. Multiplex staining depicts the immune infiltrate in colitis-induced colon cancer model. *Sci Rep*. 2019 Sep 2;9(1):12645. doi: 10.1038/s41598-019-49164-3.
- 107** Grisard E, Coan M, Cesaratto L, Rigo I, Zandonà L, Paulitti A, Andreuzzi E, Rampioni Vinciguerra GL, Poletto E, Del Ben F, Brisotto G, Biscontin E, Turetta M, Dassi E, Mirnezami A, Canzonieri V, Vecchione A, **Baldassarre G**, Mongiat M, Spizzo R, Nicoloso MS. Sleeping beauty genetic screen identifies miR-23b::BTBD7 gene interaction as crucial for colorectal cancer metastasis. *EBioMedicine*. 2019 Aug;46:79-93. doi: 10.1016/j.ebiom.2019.06.044.
- 106** Rampioni Vinciguerra GL, Antonelli G, Citron F, Berardi G, Angeletti S, **Baldassarre G**, Vecchione A, Di Giulio E, Pillozzi E. Pathologist second opinion significantly alters clinical management of pT1 endoscopically resected colorectal cancer. *Virchows Arch*. 2019 Jun 17. doi: 10.1007/s00428-019-02603-y
- 105** Sonogo M, Pellarin I, Costa A, Vinciguerra GLR, Coan M, Kraut A, D'Andrea S, Dall'Acqua A, Castillo-Tong DC, Califano D, Losito S, Spizzo R, Couté Y, Vecchione A, Belletti B, Schiappacassi M, **Baldassarre G**. USP1 links platinum resistance to cancer cell dissemination by regulating Snail stability. *Sci Adv*. 2019 May 8;5(5):eaav3235. doi: 10.1126/sciadv.aav3235.
- 104** Rampioni Vinciguerra GL, Citron F, Segatto I, Belletti B, Vecchione A, **Baldassarre G**. p27kip1 at the crossroad between actin and microtubule dynamics. *Cell Div*. 2019 Apr 1;14:2. doi: 10.1186/s13008-019-0045-9.
- 103** Segatto I, De Marco Zompit M, Citron F, D'Andrea S, Rampioni Vinciguerra GL, Perin T, Berton S, Mungo G, Schiappacassi M, Marchini C, Amici A, Vecchione A, **Baldassarre G\*** and Belletti B\*. Stathmin is required for normal mouse mammary gland development and  $\Delta$ 16HER2-driven tumorigenesis. *Cancer Res*. 2019 Jan 15;79(2):397-409.\* Last and corresponding authors
- 102** De Carlo E, Schiappacassi M, Urbani M, Doliana R, **Baldassarre G**, Da Ros V, Santarossa S, Chimienti E, Berto E, Fratino L, Bearz A. Therapeutic decision based on molecular detection of resistance mechanism in an ALK-rearranged lung cancer patient: a case report. *Oncotargets and Therapy*. 2018 Dec 10;11:8945-8950.
- 101** De Marco C, Rinaldo N, De Vita F, Forzati F, Caira E, Iovane V, Paciello O, Montanaro D, D'Andrea S, **Baldassarre G**, Papparella S, Malanga D, Baldi A and Viglietto G. The T197A knock-in model of Cdkn1b gene to study the effects of p27 restoration in vivo. *Molecular and Cancer Therapeutic*. 2019 Feb;18(2):482-493.
- 100** Segatto I, **Baldassarre G** and Belletti B. STAT3 in Breast Cancer Onset and Progression: A Matter of Time and Context. *Int J Mol Sci* 2018 Sep 18;19(9). pii: E2818.
- 99** Coan M, Rampioni Vinciguerra GL, Cesaratto L, Gardenal E, Bianchet R, Dassi E, Vecchione A, **Baldassarre G**, Spizzo R, Nicoloso MS. Exploring the Role of Fallopian Ciliated Cells in the Pathogenesis of High-Grade Serous Ovarian Cancer. *Int J Mol Sci*. 2018 Aug 24;19(9). pii: E2512.
- 98** Cusan M, Mungo G, De Marco Zompit M, Segatto I, Belletti B, and **Baldassarre G**. Landscape of CDKN1B Mutations in Luminal Breast Cancer and Other Hormone-Driven Human Tumors. *Front Endocrinol (Lausanne)*. 2018 Jul 17;9:393
- 97** Nicoloso MS, Schiappacassi M, Dall'Acqua A, D'Andrea S, Benevol S, Sorio R, Canzonieri V, Giorda G, and **Baldassarre G**. SRSF2 mutations in epithelial ovarian cancer. *Cancer Breaking News* 2017 5(3):25-29. doi: 10.19156/cbn.2017.0056.
- 96** Dall'Acqua A, Sonogo M, Pellizzari I, Pellarin I, Canzonieri V, D'Andrea S, Benevol S, Sorio R, Giorda G, Califano D, Bagnoli M, Militello L, Mezzanzanica D, Chiappetta G, Armenia J, Belletti B, Schiappacassi M and **Baldassarre G**. CDK6 protects

epithelial ovarian cancer from platinum-induced death via FOXO3 regulation. *EMBO Mol Med.* 2017 Oct;9(10):1415-1433. doi: 10.15252/emmm.201607012.

**95** Sonogo M, Pellizzari I, Dall'Acqua A, Pivetta E, Lorenzon I, Benevol S, Bomben R, Spessotto P, Roberto Sorio, Gattei V, Belletti B, Schiappacassi M and **Baldassarre G**. Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells. *Scientific Reports* 2017 Aug 2;7(1):7104.

**94** Berton S, Cusan M, Segatto I, Citron F, D'Andrea S, Benevol S, Avanzo M, Dall'Acqua A, Schiappacassi M, Bristow RG, Belletti B, and **Baldassarre G**. Loss of p27kip1 increases genomic instability and induces radio-resistance in luminal breast cancer cells. *Scientific Reports.* 2017 Jul 14;7(1):5449.

**93** Citron F, Armenia J, Franchin G, Polesel J, Talamini R, D'Andrea S, Sulfaro S, Croce CM, Klement W, Otasek D, Pastrello C, Tokar T, Jurisica I, French D, Bomben R, Vaccher E, Serraino D, Belletti B, Vecchione A, Barzan L & **Baldassarre G**. An integrated approach identifies mediators of local recurrence in Head & Neck Squamous Carcinoma. *Clin. Cancer Res.*, 2017 Jul 15;23(14):3769-3780.

F.to Gustavo Baldassarre

Aviano, 28.02.2023